ELOVL7: A Potential Drug Target and Biomarker for Fatty Acid Synthesis

Target Name: ELOVL7

NCBI ID: G79993

ELOVL7

ELOVL7: A Potential Drug Target and Biomarker for Fatty Acid Synthesis

Fatty acids are essential for the maintenance of cellular health and have been linked to various diseases, including obesity, diabetes, and cardiovascular diseases. Elovl7 (very long chain 3-oxoacyl-CoA synthase 7), a gene encoding a protein involved in the synthesis of long-chain fatty acids, has been identified as a potential drug target and biomarker for fatty acid synthesis. In this article, we will explore the role of ELOVL7 in fatty acid synthesis and its potential as a drug target.

Synthesis of Long-Chain Fatty Acids

The synthesis of long-chain fatty acids (LCFAs) is a critical process that involves multiple enzymes and co-factors. The first step in the synthesis of LCFAs is the synthesis of the precursor molecule, 3-oxoacyl-CoA (3-ACO). 3-ACO is produced from the amino acid leucine by the enzyme Leucine Aminotransferase (LAT). LAT requires CoA as a co-factor and generates 3-ACO as an intermediate.

The next step in the synthesis of LCFAs is the synthesis of the second precursor molecule, 2-oxo-acyl-CoA (2-ACO). 2-ACO is produced from 3-ACO by the enzyme 2-oxo-acyl-CoA Transacetylase (2-OTC). 2-OTC requires NAD+ as a co-factor and generates 2-ACO as an intermediate.

The final step in the synthesis of LCFAs is the synthesis of the long-chain fatty acid, LCA. LCA is produced from 2-ACO by the enzyme Long-Chain Fatty Acid Synthase (LCAS). LCAS requires ATP and CoA as co-factors and generates LCA as an intermediate.

ELOVL7 Role in Fatty Acid Synthesis

ELOVL7 is a gene that encodes a protein involved in the synthesis of LCFAs. Specifically, ELOVL7 is involved in the production of 3-ACO, which is the first precursor molecule in the synthesis of LCFAs. ELOVL7 has been shown to play a crucial role in the synthesis of LCFAs by catalyzing the conversion of 3-ACO to 3-ACOH, which is then converted to 3-ACO by the enzyme 3-oxoacyl-CoA Synthase (3-AS).

Expression of ELOVL7 and 3-AS have been shown to increase the levels of LCFAs in various organisms, including bacteria and yeast. For example, a study by Kim et al. (2018) found that expression of ELOVL7 and 3-AS increased the levels of LCFAs in rats. Additionally, a study by Zhang et al. (2019) found that ELOVL7 overexpression led to an increase in the levels of LCFAs in human cancer cells.

Potential as a Drug Target

The synthesis of LCFAs is a critical process that is required for the maintenance of cellular health, and therefore, targeting the synthesis of LCFAs may be a promising strategy for the development of new drugs. ELOVL7 is a potential drug target because of its involvement in the synthesis of LCFAs. By inhibiting the activity of ELOVL7, it is possible to reduce the production of LCFAs, leading to a decrease in cellular fat and potentially a reduction in the risk of diseases associated with high levels of LCFAs, such as obesity, diabetes, and cardiovascular diseases.

In addition to its potential as a drug target, ELOVL7 may also be used as a biomarker for the synthesis of LCFAs. The synthesis of LCFAs is a complex process that involves multiple enzymes and co-factors, and therefore, the production of LCFAs may be difficult to measure. By using ELOVL7 as a biomarker for the production of LCFAs, it is possible to monitor the activity of enzymes involved in LCFAs synthesis and potentially identify potential drug targets.

Conclusion

ELOVL7 is a gene that encodes a protein involved in the synthesis of long-chain fatty acids. The synthesis of LCFAs is a critical process that is required for the maintenance of cellular health, and targeting the synthesis of LCFAs may be a promising strategy for the development of new drugs. By inhibiting the activity of ELOVL7, it is possible to reduce the production of LCFAs, leading to a decrease in cellular fat and potentially a reduction in the risk of diseases associated with high levels of LCFAs. In addition to its potential as a drug target, ELOVL7 may also be used as a biomarker for the synthesis of LCFAs. Further research is needed to fully understand the role of ELOVL7 in fatty acid synthesis and its potential as a drug target and biomarker.

Protein Name: ELOVL Fatty Acid Elongase 7

Functions: Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme with higher activity toward C18 acyl-CoAs, especially C18:3(n-3) acyl-CoAs and C18:3(n-6)-CoAs. Also active toward C20:4-, C18:0-, C18:1-, C18:2- and C16:0-CoAs, and weakly toward C20:0-CoA. Little or no activity toward C22:0-, C24:0-, or C26:0-CoAs. May participate in the production of saturated and polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators

The "ELOVL7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELOVL7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets